Eclectic Associates’s AbbVie ABBV Stock Holding History

Eclectic Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Sell	5,575 -268	-5%	-$57.7K	0.16%	70
2026 Q1	$1.27M	Sell	5,843 -9	-0.2%	-$2K	0.17%	69
2025 Q4	$1.34M	Buy	5,852 +45	+0.8%	+$10.3K	0.21%	64
2025 Q3	$1.34M	Buy	5,807 +4	+0.1%	+$815	0.25%	60
2025 Q2	$1.08M	Hold	5,803	–	–	0.23%	64
2025 Q1	$1.22M	Hold	5,803	–	–	0.33%	60
2024 Q4	$1.03M	Buy	5,803 +4,756	+454%	+$874K	0.31%	63
2024 Q3	$207K	Buy	+1,047	New	+$195K	0.08%	99
2022 Q1	–	Sell	-1,872	Closed	-$253K	–	74
2021 Q4	$253K	Buy	+1,872	New	+$221K	0.16%	65

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Eclectic Associates's ABBV Position: Q2 2026 in Review

Eclectic Associates reduced its AbbVie (ABBV) stake by 4.6% in Q2 2026, selling an estimated $57.7K and leaving 5,575 shares worth $1.4M. The position accounts for 0.16% of the portfolio, ranked #70.

Eclectic Associates first reported a position in ABBV in Q4 2021 and has held it in 9 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Eclectic Associates held 5,575 shares of AbbVie worth $1.4M as of Q2 2026.
Eclectic Associates sold 268 AbbVie shares in Q2 2026, an estimated $57.7K.
AbbVie made up 0.16% of Eclectic Associates's portfolio in Q2 2026, its #70 holding.
Eclectic Associates first reported a position in AbbVie in Q4 2021 and has held it in 9 quarters since.
803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eclectic Associates's 13F filing for Q2 2026, filed 7 Jul 2026.